Evaluation of pomegranate peel extract in bladder infection

Evaluation of the oral formulation of pomegranate peel extract efficacy for the treatment of cystitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046990N15

Enrollment

Registered

2024-01-03

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis. Cystitis, unspecified

Interventions

Intervention 1: Intervention group: The intervention group will receive capsules containing 250 mg of pomegranate peel extract three times a day for one week. Intervention 2: Control group: The contro

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Acute cystitis based on clinical symptoms Signing a written informed consent

Exclusion criteria

Exclusion criteria: Simultaneous use of phenazopyridine Taking cranberry and probiotic supplements History of allergy to pomegranate and its derivatives Taking warfarin or cyclosporine and tacrolimus History of severe constipation or hemorrhoids

Design outcomes

Primary

Measure	Time frame
Score of improvement of disease symptoms. Timepoint: At the beginning of the study and then at the end of the third, fifth day and if the symptoms remain, on the seventh day. Method of measurement: Acute cystitis symptom scoring criteria evaluation questionnaire (ACSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Elyasi

Mashhad University of Medical Sciences

elyasis@mums.ac.ir+98 51 3180 1588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026